-
- 抗原 See all Klra4 products
- Klra4 (Killer Cell Lectin-Like Receptor, Subfamily A, Member 4 (Klra4))
- 适用
- 小鼠
- 宿主
- 大鼠
- 克隆类型
- 单克隆
- 标记
- This Klra4 antibody is conjugated to FITC
- 应用范围
- Flow Cytometry (FACS)
- 纯化方法
- The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions. The solution is free of unconjugated FITC.
- 克隆位点
- 4E5
- 亚型
- IgG2a kappa
-
- 应用备注
- Optimal working dilution should be determined by the investigator.
- 限制
- 仅限研究用
-
- 浓度
- 0.5 mg/mL
- 缓冲液
- Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.
- 储存液
- Sodium azide
- 注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 注意事项
- Protect from prolonged exposure to light. Do not freeze.
- 储存条件
- 4 °C
- 储存方法
- The antibody solution should be stored undiluted between 2°C and 8°C.
-
- 抗原
- Klra4 (Killer Cell Lectin-Like Receptor, Subfamily A, Member 4 (Klra4))
- 别名
- Ly49D (Klra4 产品)
- 别名
- Chok antibody, Klra32 antibody, Ly-49d antibody, Ly49d antibody, ly49r<129> antibody, killer cell lectin-like receptor, subfamily A, member 4 antibody, Klra4 antibody
- 背景
- Ly49D is a type II transmembrane protein belonging to the Ly49 family of NK-cell receptors in the C-type lectin superfamily. Ly49D is expressed on subsets of natural killer (NK) cells in C57BL/6, C3H/He and SJL mouse strains, but not Balb/c, DBA/2, AKR and CBA/J. The receptors form homodimers that bind to MHC class I alloantigens. Unlike inhibitory Ly49 family members, Ly49D lacks a cytoplasmic immunoreceptor tyrosine-based inhibitory motif (ITIM) but contains a cytoplasmic immunoreceptor tyrosine-based activation motif. The activating receptor Ly49D delivers stimulatory signals for target cell lysis upon interacting with H2-Dd, Dr and Dsp2, but not with H2b or H2k class I antigens. Cross-linking of Ly49D activates intracellular kinase activity and calcium mobilization in NK cells. In 129/J mice, 4E5 antibody cross-reacts with Ly49O, LY49R and Ly49V.
-
You are here:
